Emcure Pharmaceuticals Ltd.
NSE: EMCURE · Pharmaceuticals
Snapshot
Unlock Emcure Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emcure Pharmaceuticals Limited is a Pune-based pharmaceutical company that develops, manufactures, and markets a diverse range of healthcare solutions. The company operates across multiple therapeutic areas including gynecology, oncology, anti-infectives, and cardiovascular health.
Business Model
The company generates revenue by developing and selling pharmaceutical products under various established brand names such as Orofer XT and Metpure XL. It focuses on providing affordable healthcare solutions across both domestic and international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the company's extensive portfolio across high-demand therapeutic segments and its commitment to expanding its global footprint. Continued investment in product development remains a core focus for sustaining market competitiveness.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to product recalls or manufacturing site restrictions.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines may impact profit margins in the domestic market.
- R&D Execution. The ability to successfully develop and commercialise new drug formulations is critical to maintaining market share against generic competitors.
- Currency Volatility. As an entity with international operations, the company is exposed to fluctuations in foreign exchange rates that can affect export profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Emcure Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,683 Cr
TTM · consolidated
NET PROFIT
₹1,019 Cr
TTM · consolidated
EPS
₹53.35
TTM · consolidated
RETURN ON EQUITY
21.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
27.3%
TTM · consolidated
P/E
36.4×
Q1 FY27 · consolidated
EV/EBITDA
19.4x
Q1 FY27 · consolidated
EBITDA MARGIN
20.6%
TTM · consolidated
NET PROFIT MARGIN
11.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Emcure Pharmaceuticals Ltd.EMCURE | ₹37,585 Cr | 36.4× | 19.41 | 18.4% | 20.6% | 21.7% | 27.3% | +49.1% |
Ajanta Pharmaceuticals Ltd.AJANTPHARM | ₹44,578 Cr | 39.4× | 26.54 | 20.2% | 29.1% | 27.3% | 34.4% | +49.3% |
J.B. Chemicals & Pharmaceuticals Ltd.JBCHEPHARM | ₹38,730 Cr | 53.2× | — | 5.9% | 28.1% | 18.7% | 23.9% | — |
Wockhardt Ltd.WOCKPHARMA | ₹37,856 Cr | 82.7× | 44.48 | 18.4% | 25.1% | 8.9% | 10.4% | +39.6% |
Sai Life Sciences Ltd.SAILIFE | ₹34,142 Cr | 89.8× | 48.72 | — | 31.2% | 15.7% | 19.8% | +73.7% |
Neuland Laboratories Ltd.NEULANDLAB | ₹28,854 Cr | 55.4× | 36.50 | 78.3% | 33.5% | 29.3% | 35.4% | +39.8% |
As of Q1 FY27
Financials
Emcure Pharmaceuticals Ltd.
NSE: EMCURE · Pharmaceuticals
Snapshot
Unlock Emcure Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emcure Pharmaceuticals Limited is a Pune-based pharmaceutical company that develops, manufactures, and markets a diverse range of healthcare solutions. The company operates across multiple therapeutic areas including gynecology, oncology, anti-infectives, and cardiovascular health.
Business Model
The company generates revenue by developing and selling pharmaceutical products under various established brand names such as Orofer XT and Metpure XL. It focuses on providing affordable healthcare solutions across both domestic and international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the company's extensive portfolio across high-demand therapeutic segments and its commitment to expanding its global footprint. Continued investment in product development remains a core focus for sustaining market competitiveness.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to product recalls or manufacturing site restrictions.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines may impact profit margins in the domestic market.
- R&D Execution. The ability to successfully develop and commercialise new drug formulations is critical to maintaining market share against generic competitors.
- Currency Volatility. As an entity with international operations, the company is exposed to fluctuations in foreign exchange rates that can affect export profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Emcure Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,683 Cr
TTM · consolidated
NET PROFIT
₹1,019 Cr
TTM · consolidated
EPS
₹53.35
TTM · consolidated
RETURN ON EQUITY
21.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
27.3%
TTM · consolidated
P/E
36.4x
Q1 FY27 · consolidated
EV/EBITDA
19.4x
Q1 FY27 · consolidated
EBITDA MARGIN
20.6%
TTM · consolidated
NET PROFIT MARGIN
11.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27